Novo Nordisk stock surges on hopes Wegovy pill approval will deliver 'redemption' for investors
The FDA on Monday approved the first-ever GLP-1 pill for weight loss from the Danish pharmaceutical giant.
TL;DR
- Novo Nordisk secured FDA approval for the first GLP-1 pill for weight loss.
- The approval is seen as a significant boost for Novo Nordisk's stock after a challenging year.
- The oral Wegovy is set to launch in the U.S. in early January 2026.
- This approval gives Novo Nordisk a head start over competitor Eli Lilly.
- Novo's pill has shown an average weight loss of 16.6% in trials, compared to 12.4% for Eli Lilly's oral drug.
- Concerns remain about Eli Lilly's potential to retain market share and the compliance implications of Novo's drug's administration.
- Novo's shares had previously fallen significantly in 2025 due to competition and demand issues.